A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Dec 2017 Status changed from not yet recruiting to recruiting.
- 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 31 Oct 2017.
- 24 Aug 2017 New trial record